- Drug X has a receptor binding affinity (Kd) of 2 nM and an EC50 for a functional response of 20 nM. Drug Y, a full agonist for the same receptor, has a Kd of 10 nM and an EC50 of 10 nM. Both drugs produce the same Emax. What can be concluded from this data?
Answer: Drug Y is more potent than Drug X, and the signal transduction for Drug X is more efficient.
Potency is measured by EC50, not Kd. Drug Y (EC50=10 nM) is more potent than Drug X (EC50=20 nM). Affinity (inversely related to Kd) is a measure of how tightly a drug binds to a receptor. Drug X (Kd=2 nM) has a higher affinity than Drug Y (Kd=10 nM). The fact that Drug Y is more potent despite having lower affinity suggests that the efficiency of coupling between receptor binding and response (signal transduction) is greater for Drug Y. For Drug Y, EC50=Kd, suggesting no spare receptors and direct coupling. For Drug X, EC50 > Kd, which is an unusual relationship suggesting inefficient signal transduction, where a large proportion of receptors must be occupied to elicit a half-maximal response.
- Chronic administration of a full agonist often leads to receptor desensitization and downregulation, causing pharmacodynamic tolerance. How would this phenomenon typically alter the agonist's log dose-response curve?
Answer: A parallel rightward shift and a depression of the maximal response.
Pharmacodynamic tolerance typically manifests in two ways on the dose-response curve. First, a higher concentration of the drug is needed to produce the same effect, which is represented by a rightward shift of the curve (an increase in EC50, i.e., decreased potency). Second, receptor downregulation can reduce the total number of available receptors, leading to a decrease in the maximal achievable response (a decrease in Emax, i.e., decreased efficacy). Therefore, a rightward shift combined with a depression of the Emax is the classic representation of tolerance.
- A patient with stable angina is switched from Nitroglycerin sublingual tablets to Isosorbide mononitrate oral tablets for prophylaxis. The clinician explains that while both drugs can achieve the same degree of coronary vasodilation, a 0.4 mg dose of nitroglycerin is equivalent to a 20 mg dose of isosorbide mononitrate. Which statement correctly describes the pharmacological relationship based on this information?
Answer: Nitroglycerin and isosorbide mononitrate have comparable efficacy, but nitroglycerin is more potent.
Efficacy refers to the maximal effect a drug can produce. The stem states that both drugs can achieve the same degree of coronary vasodilation, meaning they have comparable efficacy. Potency refers to the amount of drug needed to produce a given effect. Since a much smaller dose of nitroglycerin (0.4 mg) is needed to produce an effect equivalent to a larger dose of isosorbide mononitrate (20 mg), nitroglycerin is significantly more potent.
- Drug A is an agonist with an EC50 of 10 nM. When co-administered with Compound Z, the dose-response curve for Drug A shifts to the right, and the new apparent EC50 is 100 nM, but the Emax is unchanged. When Drug A is co-administered with Compound Y, the Emax is reduced by 50%, and the EC50 is unchanged. Which statement best describes Compounds Y and Z?
Answer: Compound Z is a competitive antagonist, and Compound Y is a non-competitive antagonist.
A competitive antagonist binds reversibly to the active site, causing a parallel rightward shift in the agonist dose-response curve (increase in EC50) without affecting the maximal response (Emax). This matches the description of Compound Z. A non-competitive antagonist binds to an allosteric site or irreversibly to the active site, which reduces the number of functional receptors available to the agonist. This results in a downward shift of the curve (decrease in Emax) without changing the agonist's EC50 for the remaining receptors. This matches the description of Compound Y.
- A patient with heart failure experiences a progressive downregulation of β1-adrenergic receptors in the myocardium over several years. The patient is treated with dobutamine, a β1-agonist. Assuming no spare receptors for dobutamine's inotropic effect, how would the dose-response curve for dobutamine in this patient most likely change over time compared to a healthy individual?
Answer: A decrease in the maximal response, indicating decreased efficacy.
Downregulation of receptors reduces the total number of receptors available for the agonist to bind. In the absence of spare receptors, the maximal possible physiological response is directly proportional to the number of receptors. Therefore, a reduction in receptor number will lead to a decrease in the maximal effect (Emax) that can be achieved, regardless of the agonist concentration. This represents a decrease in efficacy. Potency (EC50) may not be significantly affected, but the ceiling of the effect will be lower.
- An inverse agonist is a drug that binds to the same receptor as an agonist but induces a pharmacological response opposite to that of the agonist. How would the efficacy of a full inverse agonist be characterized compared to a neutral antagonist and a full agonist?
Answer: It has negative efficacy, whereas a neutral antagonist has zero efficacy.
Efficacy is a measure of the ability of a drug-receptor complex to produce a response. A full agonist has an efficacy of +1 (or 100%). A neutral antagonist binds to the receptor but has no effect on its constitutive activity, so its efficacy is defined as 0. An inverse agonist binds and reduces the receptor's basal (constitutive) activity, producing an effect opposite to the agonist. This is defined as negative efficacy (e.g., -1 for a full inverse agonist).
- A new drug (Drug N) is being compared to a standard drug (Drug S). The Emax of Drug N is 80% of the Emax for Drug S. The EC50 of Drug N is 1 µM, while the EC50 of Drug S is 10 µM. Which statement accurately summarizes the comparison?
Answer: Drug N is 10 times more potent and has 20% lower efficacy than Drug S.
Potency is inversely proportional to the EC50. Drug N has an EC50 of 1 µM and Drug S has an EC50 of 10 µM. Since Drug N's EC50 is 10 times smaller, it is 10 times more potent. Efficacy is the maximal effect (Emax). Drug N's Emax is 80% of Drug S's Emax, meaning it has lower efficacy. Specifically, its efficacy is 20% lower. Therefore, Drug N is more potent but less efficacious than Drug S.
- An experimental drug is a positive allosteric modulator (PAM) of the GABAA receptor. It does not activate the receptor on its own but enhances the effect of GABA. How would the administration of this PAM alter the dose-response curve for GABA?
Answer: It would shift the curve to the left, increasing GABA's apparent potency.
A positive allosteric modulator binds to a site on the receptor different from the agonist binding site and increases the agonist's affinity or signaling efficiency. This means that a lower concentration of the agonist (GABA) is needed to produce a given effect. On a dose-response curve, this is represented as a leftward shift, which corresponds to an increase in apparent potency. Most PAMs of this type do not change the maximal response (Emax) of the endogenous full agonist, so efficacy remains unchanged.
- Drug F is a full agonist at the μ-opioid receptor. Drug P is a partial agonist at the same receptor, but it has a 10-fold higher affinity (and thus higher potency) than Drug F. A patient is receiving a high dose of Drug F, which produces a maximal analgesic response. If Drug P is then administered, what is the most likely outcome on the overall analgesic effect?
Answer: The analgesic effect will decrease because Drug P has lower intrinsic efficacy.
When a partial agonist is administered in the presence of a full agonist, it acts as a competitive antagonist. Because Drug P has higher affinity (potency), it will displace the full agonist (Drug F) from the μ-opioid receptors. Since Drug P has lower intrinsic efficacy, replacing the full agonist with a partial agonist at the receptor site will result in a net decrease in the overall analgesic effect, moving it from the Emax of Drug F toward the lower Emax of Drug P.
- Two drugs, Finasteride and Dutasteride, are 5-alpha reductase inhibitors used to treat benign prostatic hyperplasia. Dutasteride inhibits both type I and type II isoenzymes, while Finasteride primarily inhibits the type II isoenzyme. Clinically, dutasteride can suppress circulating DHT levels by over 90%, whereas finasteride suppresses them by about 70%. Based on this mechanism and clinical effect, which statement is most accurate?
Answer: Dutasteride has higher efficacy than finasteride.
Efficacy refers to the maximal effect a drug can produce. Since dutasteride can achieve a greater maximal suppression of DHT (90%) compared to finasteride (70%), it is considered to have higher efficacy. The information given does not allow for a direct comparison of potency (the dose required to achieve a specific level of inhibition), only the maximal possible effect.
- A researcher compares two drugs, Drug X and Drug Y, on a tissue preparation. In the presence of a competitive antagonist, the log dose-response curve for Drug X shifts 50-fold to the right, but the maximal response is unchanged. In the presence of the same concentration of the same antagonist, the curve for Drug Y shifts 10-fold to the right, with its maximal response also unchanged. Both Drug X and Y are full agonists. What is the most likely explanation for this difference?
Answer: The system has more spare receptors for Drug X than for Drug Y.
The magnitude of the rightward shift caused by a competitive antagonist is influenced by the presence of spare receptors. When a large receptor reserve exists, a higher concentration of the antagonist is needed to overcome the agonist's effect, resulting in a larger shift in the dose-response curve. Since the shift for Drug X (50-fold) is greater than for Drug Y (10-fold) with the same antagonist concentration, it implies that the tissue has a greater functional reserve or more spare receptors for Drug X's action compared to Drug Y's.
- A clinician describes a new beta-agonist for asthma as being 'stronger' than albuterol. Pharmacological data reveals the new drug produces 15% more bronchodilation at its maximal effective dose compared to albuterol. However, the dose required to produce 50% of its own maximal effect is twice the dose required for albuterol to achieve 50% of its maximal effect. How should this new drug be characterized in pharmacological terms?
Answer: Lower potency and higher efficacy than albuterol.
Efficacy refers to the maximal response (Emax). Since the new drug produces more bronchodilation (15% more) at its maximal dose, it has higher efficacy than albuterol. Potency refers to the concentration or dose (EC50) required to produce 50% of the drug's own maximal effect. Since the new drug requires twice the dose to reach its half-maximal effect, it is less potent than albuterol. The term 'stronger' is ambiguous, and the student must parse the data for potency (dose) and efficacy (maximal effect) separately.
- Epinephrine and salmeterol are both used for bronchodilation but in different clinical contexts. Epinephrine is a non-selective adrenergic agonist that produces maximal bronchodilation in emergency situations like anaphylaxis. Salmeterol is a selective β2-agonist that produces submaximal bronchodilation but requires lower concentrations to achieve 50% of its maximal effect compared to epinephrine at β2-receptors. What is the most accurate comparison of these drugs for bronchodilation?
Answer: Epinephrine has lower potency but higher efficacy than salmeterol.
When comparing bronchodilators, you need to distinguish between potency (concentration needed for 50% maximal effect) and efficacy (maximum possible effect). These are independent drug properties that often confuse students.
The question states that salmeterol requires "lower concentrations to achieve 50% of its maximal effect compared to epinephrine at β2-receptors." This directly defines higher potency for salmeterol. However, epinephrine produces "maximal bronchodilation" while salmeterol produces only "submaximal bronchodilation," indicating epinephrine has higher efficacy.
Answer D is correct because epinephrine has lower potency (needs higher concentrations for 50% effect) but higher efficacy (produces greater maximum bronchodilation). This explains why epinephrine is used in emergencies where maximum effect is crucial, while salmeterol's high potency makes it suitable for maintenance therapy at lower doses.
Answer A incorrectly claims epinephrine has higher potency, contradicting the given information about concentration requirements. Answer B is wrong on both counts—salmeterol doesn't have higher efficacy since it produces submaximal effects. Answer C correctly identifies epinephrine's lower potency but incorrectly states it has lower efficacy, when epinephrine actually produces the maximum possible bronchodilation.
Study tip: Remember that potency is about concentration (how much drug you need), while efficacy is about effect (how much response you can achieve). A highly potent drug that works at low doses might still have lower efficacy than a less potent drug that produces greater maximum effects.
